Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder

Abeona Therapeutics Inc ABEO has announced updated data from Phase 1/2a trial for up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).
The data showed that investigator assessment of wound healing of over 50% from baseline was present in 69% of treated wounds (n=18/26) at three years, 93% (n=14/15) at four years, 80% (n=12/15) at five years, and 80% (n=4/5) at six years.
The results were shared at the Society for Pediatric Dermatology (SPD) 46th Annual Meeting.
The data also showed that pain was absent in all treated wounds that were evaluated at three years (n=26), four years (n=15), five years (n=15), and six years (n=5) of follow up, compared with the presence of pain at baseline in 53% (n=20/38) of treated wounds.
A separate survey data showed that 76% of the treated wounds with 50% or greater healing were associated with improved pain scores, with 53% associated with "much/very much improved" pain scores.
EB-101 is an autologous, gene-corrected cell therapy currently investigated in Phase 3 VIITAL study to treat RDEB.
RDEB is a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications.
Price Action: ABEO shares are down 4.33% at $1.44 during the market session on the last check Wednesday.